Search results
Results from the WOW.Com Content Network
Eli Lilly’s once-weekly insulin injection is just as effective as daily insulin shots for managing A1C levels in diabetes, according to the latest results from two phase 3 clinical trials....
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on...
The trial randomized insulin-naïve adults with type 2 diabetes to receive efsitora once weekly or insulin degludec once daily and was also designed to assess efficacy in patients using and not using GLP-1 receptor agonists.
Eli Lilly has released promising phase 3 clinical trial results for its once-weekly insulin efsitora alfa (efsitora). The study found that efsitora reduced A1C in patients with type 2 diabetes by 1.34% compared to 1.26% for insulin dedgludec.
A once-weekly insulin helped people with type 2 diabetes manage their blood sugar (glucose) levels, with results similar to or better than daily insulin shots, according to new research.
Once-weekly insulin is meant to take the place of a once-daily long-acting shot. It could make a difference for people’s quality of life “to have to take one less shot a day,”...
A recent phase 3 clinical trial, ONWARDS 6, compared the effectiveness and safety of a once-weekly insulin icodec injection with a once-daily insulin degludec shot in adults with type 1...
Once-weekly insulin could reduce clinicians' therapeutic inertia and improve concordance for patients with type 2 diabetes who require insulin.
Type 2 diabetes is a common yet complex disorder in which the key hormone for nutrient storage, insulin, is both ineffective and insufficient in most affected patients, resulting in high...
The U.S. Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes (T2D), as an addition to diet and exercise.